Last reviewed · How we verify
Ablavar
Ablavar is a Small molecule drug developed by Lantheus Medical Imaging. It is currently in Phase 2 development.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Ablavar |
|---|---|
| Sponsor | Lantheus Medical Imaging |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases (PHASE2)
- Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease (PHASE4)
- Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar)
- Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI) (PHASE4)
- Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI (PHASE2)
- Gadofosveset Trisodium for Heart Imaging Studies
- Contrast- Enhanced Whole-Heart Coronary MRA at 3.0T (Tesla) (PHASE1)
- Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ablavar CI brief — competitive landscape report
- Ablavar updates RSS · CI watch RSS
- Lantheus Medical Imaging portfolio CI
Frequently asked questions about Ablavar
What is Ablavar?
Who makes Ablavar?
What development phase is Ablavar in?
Related
- Manufacturer: Lantheus Medical Imaging — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing